<DOC>
	<DOCNO>NCT01147627</DOCNO>
	<brief_summary>The purpose study investigate evaluate effect different intervention ( 1. exenatide , 2. insulin , 3. thiazolidinedione ) glycemic control β-cell function newly diagnose drug-naïve type 2 diabetic patient .</brief_summary>
	<brief_title>Effect Different Interventions Glycemic Control β-cell Function Newly Diagnosed Type 2 Diabetic Patients</brief_title>
	<detailed_description>One fundamental defect type 2 diabetes mellitus decline β-cell function . Exenatide target multiple metabolic disturbance type 2 diabetes exerts direct effect β-cell , indicate may contribute glucose control also delay disease progression . There trial demonstrate efficacy , safety tolerability exenatide . However , study compare effect exenatide hypoglycemic therapy β cell protective function newly diagnose drug-naïve type 2 diabetic patient . This current study thus design evaluate effect exenatide , insulin pioglitazone glycemic control β-cell function newly diagnose drug-naïve type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>newlydiagnosed type 2 diabetic patient , drug naïve age 30~70 year HbA1c 7.0~10.0 % BMI 20~35 kg/m2 , stable body weight ( ≤10 % variation ) least 3 month prior screen female patient reproductive age practice reliable method birth control throughout study acute severe chronic diabetic complication congestive heart failure ( NYHA grade Ⅲ~Ⅳ ) severe gastrointestinal disease severe osteoporosis history pathological fracture , use bisphosphonates preparation severe intercurrent illness serum aminotransferase ( ALT AST ) level high 2 time upper normal limit and/or serum creatinie≥133µmol/L ( 1.5mg/dL ) test positive glutamic acid decarboxylase antibody use weight loss drug , corticosteroid , drug know affect gastrointestinal motility , transplantation medication , investigational drug history pancreatitis serum triglyceride ≥ 5.0 mmol/L pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>exenatide</keyword>
	<keyword>premixed insulin analog</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>β-cell function</keyword>
	<keyword>glycemic control</keyword>
</DOC>